Overview

A Study of Darbepoetin Alfa for the Treatment of Anemia in Subjects With a Non-Myeloid Malignancy

Status:
Completed
Trial end date:
2003-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to compare the efficacy of darbepoetin alfa administered using a front-loading approach with subjects receiving standard weekly dosing in the treatment of anemia in subjects with a non-myeloid malignancy and receiving multicycle chemotherapy.
Phase:
Phase 3
Details
Lead Sponsor:
Amgen
Treatments:
Darbepoetin alfa